Sage Journals: Discover world-class research

Abstract

Objective

The objective of this study was to analyse autoantibodies’ titres modulation during belimumab treatment in 50 patients with systemic lupus erythematosus (SLE).

Methods

Sera were collected at belimumab start (T0) and every six months until the 24th month. Disease activity index (SLEDAI-2K) was analysed at every timepoint. High avidity anti-dsDNA was detected by radioimmunological method, anti-ENA, anti-cardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) were analysed by ELISA.

Results

Fifty patients with SLE (mean SLEDAI-2K: 7.18 ± :3), mean age of 39 ± 11 years and mean follow-up of 13 ± 7.8 years were enrolled. A significant decrease of anti-dsDNA and anti-β2GPI IgM titres was observed at all timepoints. IgG aCL titre showed significant decrease only at T18. Anti-dsDNA negativization was detected in 21%, anti-β2GPI IgG in 33% and aCL IgG in 30% of sera, mostly at T6. Anti-ribosomal showed a significant titre decrease at T6 and T12, with negative seroconversion at T18. Anti-Sm titre significantly dropped down at T6, then remained stable during the time. Significant correlations were found between anti-dsDNA and anti-ribosomal titre and between SLEDAI ratio (SLEDAI value/SLEDAI T0) and anti-ribosomal titre ratio (value/value T0).

Conclusions

Belimumab treatment induced a significant reduction of SLE-specific autoantibodies titre and IgM anti-β2GPI. Anti-ribosomal titre decrease correlates with anti-dsDNA titre and disease activity improvement.

Keywords

Anti-DNA antibodies anticardiolipin antibodies systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Stohl

Hilbert

. The discovery and development of Belimumab: The anti-BLyS-lupus connection. Nat Biotechnol 2012; 30: 69–77.

Ginzler

Wallace

Merril

, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014; 41: 300–309.

Iaccarino

Bettio

Reggia

, et al. Effects of belimumab on flare rate and expected damage progression in patients with active lupus erythematosus. Arthritis Care Res 2017; 69: 115–123.

Stohl

Hiepe

Latinis

, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cells populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 7: 2328–2337.

Petri

Orbai

Alarcòn

, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Gladman

Ibañez

Urowitz

. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.

Gladman

Ginzler

Goldsmith

, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

Harris

. Special report. The second international anticardiolipin standardization workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Ann J Clin Pathol 1990; 94: 476–484.

Balestrieri

Tincani

Spatola

, et al.

Anti-β2 glycoprotein I antibodies. A marker of antiphospholipid syndrome?

Lupus 1995; 4: 122–130.

10.

Brandt

Triplett

Alving

Scharrer

. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–1190.

11.

Figgett

Delivanti

Fairfax

Quah

Wilkinson-Berka

Mackay

. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J Autoimmun 2015; 6: 9–16.

12.

Chatham

Wallace

Stohl

, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012; 39: 1632–1640.

13.

Swaak

Groenwold

Brosveld

. Predictive value of complement profile and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359–3266.

14.

Huang

Quach

Dascalu

, et al. Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus. JCI Insight 2018; 3: 122525–122525.

15.

Malkiel

Jeganathan

Wolfson

, et al. Checkpoints for autoreactive B cells in the peripheral blood of lupus patients assessed by flow cytometry. Arthritis Rheum 2016; 68: 2210–2220.

16.

Cambridge

Leandro

Teodorescu

, et al. B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3612–3622.

17.

Sciascia

Rubini

Radin

Cecchi

Rossi

Roccatello

. Anticardiolipin and anti-beta2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome on belimumab. Ann Rheum Dis 2018; 77: 1694–1695.

18.

Yazici

Yazirli

Erkan

. Belimumab in primary antiphospholipid syndrome. Lupus 2017; 26: 1123–1124.

19.

Parra

Lopez-Dupla

Ibarretxe

, et al. Patients with systemic lupus erythematosus show an increased arterial stiffness that is predicted by IgM anti-β2-glycoprotein I and small dense high-density lipoprotein particles. Arthritis Care Res 2019; 71: 116–125.

20.

Clarke

. Anti-Sm B cell tolerance and tolerance loss in systemic lupus erythematosus. Immunol Res 2008; 41: 203–216.

21.

Carmona-Fernandes

Santos

Canhao

Fonseca

. Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: Diagnostic performance and clinical profile. BMC Med 2013; 11: 98–98.

22.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

23.

Gerli

Caponi

Tincani

, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: Prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41: 1357–1366.

24.

Toubi

Shoenfeld

. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6: 119–125.

25.

Nagai

Arinuma

Yanagida

Yamamoto

Hirohata

. Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum 2005; 52: 847–855.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB

Autoantibodies’ titre modulation by anti-BlyS treatment in systemic lupus erythematosus

Abstract

Objective

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material